Sonoma Pharmaceuticals (SNOA) announced its Q4 2025 financial results after market close.
The company reported revenue of $3.75 million, falling short of the $4.44 million estimates but up from $3.44 million a year ago, marking an 8.7% increase.
Earnings showed a loss of $0.48 per share, better than the estimated loss of $0.73 and improved from a loss of $0.07 last year.